🔗 Share this article

While the United States undertakes sweeping revisions to its immunization recommendations, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by questioning coronavirus vaccinations throughout the global health crisis and has focused upon potential fatalities following COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Program

Agency leaders were set to unveil major changes to the pediatric vaccine schedule recently, aligning the US with Denmark’s immunization schedule, it is understood – a substantial departure that would place the US at odds with much of the world with no evidence for public health gain. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to address the audience at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US so as to align more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccination policy – traditionally the domain of Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Expertise

The appointee has no obvious background in drug development, oversight or management, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a sizeable institution. She lacks background in industry regulation.”

Past heads of CBER would “be deeply familiar with legal statutes and the science of drug development”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that former directors who led the center have had.”

This division has an enormous portfolio at the FDA, Woodcock stated.

“Everybody just pays attention on the new drug program, but the generic drug division approves thousands of generic medications. There is also a biologic copycat branch, non-prescription drug unit and other areas, and all of those must be managed,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a significant leadership component to the position, which manages over 5,000 staff members. “It’s a huge leadership role, if you do it right,” she added.

Agency Reaction and Disputed Initiatives

In response to questions about Høeg’s qualifications and whether this selection indicates more teamwork among FDA leaders on immunizations, a press secretary said that the “inquiries stem from incorrect premises”.

“Her experience matches the functions of her role,” the representative explained, citing the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's new expedited review system, a controversial one-day medication authorization process that reportedly worried her predecessors. “How are these drugs being chosen for this voucher program? Who is making the decisions?” Dr. Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards less stringent rules of pharmaceuticals, aside from vaccines.”

Public Track Record on Immunizations

With immunizations, Høeg has a more documented, if problematic, history, some experts have noted. She released a research paper using non-validated crowd-sourced reports to determine the frequency of myocarditis after Covid immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are riskier than they are.

Among her “policy goals” for the incoming federal leadership included revising guidelines for recently developed shots and halting “non-essential” vaccines, she stated following the vote on a audio program. At the FDA, Dr. Høeg has allegedly floated the idea of preventing teenage boys from getting COVID-19 vaccinations.

“She’s an thorough true believer who begins with her conclusions and reverse-engineers to retrofit the evidence in a highly disingenuous, fraudulent way,” Howard stated.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|